Bannerbild German Brest Group

November 2018: Exploratory analysis on obese breast cancer patients from the PANTHER trial

30.11.2018

Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment has been published in the Annals of Oncology.

An exploratory analysis of tailored dosing in the PANTHER trial demonstrated that obese patients (BMI≥30) treated with tailored dose-dense chemotherapy had improved breast cancer relapse-free survival (BCRFS) compared to non-obese ones (BMI<30) (HR = 0.51 [95% CI 0.30-0.89]; p=0.02). Furthermore, the tailored dose-dense chemotherapy was associated with improved BCRFS compared to standard anthracycline/taxane containing regimen only in obese patients (HR=0.49 [95%CI 0.26-0.90]; p=0.022, test for interaction p=0.175). There were no differences in terms of toxicity between the BMI groups. Hence, the use of tailored dose-dense regimen as adjuvant chemotherapy can potentially improve outcomes in obese patients without increasing toxicity and should be pursued in further clinical studies.

Matikas A, Foukakis T, Moebus V, Greil R, Bengtsson NO, Steger GG, Untch M, Johansson H, Hellström M, Malmström P, Gnant M, Loibl S, Bergh J. Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: Further results from the prospective PANTHER study with focus on obese patients. Ann Oncol. 2018 Oct 24 [Epub ahead of print].

Link in PubMed


News

  • 05.11.2018 October 2018: Long-term survival analysis of GeparSixto trial

    The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.

    Mehr ...
  • 15.10.2018 GBG Research at ESMO

    Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.

    Mehr ...
  • 11.10.2018 BIG newsletter no 9 is out

    We’re delighted to announce that the BIG newsletter BIG Research in Focus, Issue 9 is out and has been published on BIG’s website.

    Mehr ...
  • 27.09.2018 Paper of the month: models for pCR

    Paper of the month: models for pCR

    A statistical research study that aimed to develop an empirical model for predicting the magnitude of the treatment effects on survival endpoints based on the treatment effects on pathological complete response (pCR) has been published in the Contemporary Clinical Trials.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd